Historically important Intellectual property related to the Australian Life Sciences sector

Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (21 August 2018)

Here are what we consider to have been the most notable PCT patent applications relevant to the Life Sciences sector in Australia and New Zealand up to 27 August 1998:

Australia

WO/1998/036054, Novel molecules, Amrad, 20 August 1998
WO/1998/033917, Vascular Endothelial Growth Factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof, Ludwig Institute for Cancer Research and University of Helsinki, 6 August 1998
WO/1998/032769, Antigen, Auspharm International Ltd, 30 July 1998
WO/1998/031819, Expression in yeast of antigenically active, recombinant hybrid glutamic acid decarboxylase, Montech Medical Developments Pty Ltd and Rondole Pty Ltd, 23 July 1998
WO/1998/031739, A process for preparing polymeric microgels, University of Melbourne, 23 July 1998
WO/1998/030124, Insect repellent substrate for headwear, Lice Busters International Pty Ltd, 16 July 1998
WO/1998/027996, A method of treatment and prophylaxis, Amrad, 2 July 1998
WO/1998/027927, Apparatus and method for coating a material, Scientec Research Pty Ltd, 2 July 1998
WO/1998/027805, Antimicrobial proteins, Cooperative Research Centre for Tropical Plant Pathology, 2 July 1998
WO/1998/026784, A method for preventing or controlling cataract, University of Sydney, 25 June 1998
WO/1998/023639, ShK toxin compositions and methods of use, University of Florida, University of California, Bachem Bioscience and Biomolecular Research Institute, 4 June 1998
WO/1998/023291, Percutaneous delivery system, Soltec Research Pty Ltd, 4 June 1998
WO/1998/020023, Therapeutic and diagnostic agents capable of modulating cellular responsiveness to cytokines, Walter and Eliza Hall Institute of Medical Research, 14 May 1998
WO/1998/018918, Stable expression of triple helical proteins, Commonwealth Scientific and Industrial Research Organisation, 7 May 1998
WO/1998/017320, Use of hyaluronan in gene therapy, Hyal Pharmaceutical Corporation, 30 April 1998
WO/1998/015267, Method for the treatment of neurological or neuropsychiatric disorders, Clarencew Pty Ltd, 16 April 1998
WO/1998/013379, Method of cell inhibition using polypeptides derived from the venom of the Australian jumper ant Myrmecia pilosula, Northern Sydney Area Health Service, 2 April 1998
WO/1998/008533, Sustained peptide-release formulation, Peptech, 5 March 1998
WO/1998/008503, Therapeutic methods and compositions involving isoflavones, Novogen, 5 March 1998
WO/1998/007832, Recombinant Vascular Endothelial cell Growth Factor D (VEGF-D), Ludwig Institute for Cancer Research and University of Helsinki, 26 February 1998
WO/1998/005768, Improved nucleic acids encoding a chimeric glycosyltransferase, Austin Research Institute, 12 February 1998
WO/1998/003573, Angiogenic inhibitory compounds, Biomolecular Research Institute, 29 January 1998
WO/1998/001465, Neuroactive peptide, Howard Florey Institute of Experimental Physiology and Medicine, 15 January 1998
WO/1997/047644, T cell antigen receptor peptides, Northern Sydney Area Health Services, 18 December 1997
WO/1997/045449, Dendritic cell receptor, Derek Hart, 4 December 1997
WO/1997/045444, EBV CTL epitopes, Queensland Institute of Medical Research, Commonwealth Scientific and Industrial Research Organisation, University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Biotech Australia Pty Ltd and CSL Ltd, 4 December 1997
WO/1997/043005, Targeted hysteresis hyperthermia as a method for treating diseased tissue, Paragon Medical, Bruce Gray and Stephen Jones, 20 November 1997
WO/1997/042958, Treatment of asthma and airway diseases, Amrad, 20 November 1997
WO/1997/041886, Stimulation of host defence mechanisms against tumors, Pharma Pacific Pty Ltd, 13 November 1997
WO/1997/041884, Method of treatment, Pharma Pacific Pty Ltd, 13 November 1997
WO/1997/041839, Taste masked liquid suspensions, F.H. Faulding & Co., 13 November 1997
WO/1997/038688, Methods of treating immunopathologies using polyunsaturated fatty acids, Peptech and Women's and Children's Hospital Adelaide, 23 October 1997
WO/1997/038681, A method for detection of potential co-antioxidants, Heart Research Institute, 23 October 1997
WO/1997/037013, Asymmetric hammerhead ribozymes, Commonwealth Scientific and Industrial Research Organisation, 9 October 1997
WO/1997/036923, Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis, University of Melbourne and Victorian Dairy Industry Authority, 9 October 1997
WO/1997/035971, A novel mammalian gene, BCL-W, belongs to the Bcl-2 family of apoptosis-controlling genes, Amrad, 2 October 1997
WO/1997/034639, Animal model for transplantation, Fremantle Hospital, 25 September 1997
WO/1997/034615, Enhancement of microbial colonisation of the gastrointestinal tract, University of New South Wales, Burns Philp, Commonwealth Scientific and Industrial Research Organisation, Arnott's Biscuits, Gist-Brocades and Goodman Fielder, 25 September 1997
WO/1997/034592, Selection and/or enhancement of resident microorganisms in the gastrointestinal tract, University of New South Wales, Burns Philp, Commonwealth Scientific and Industrial Research Organisation, Arnott's Biscuits, Gist-Brocades and Goodman Fielder, 25 September 1997
WO/1997/034591, Alteration of microbial populations in the gastrointestinal tract, University of New South Wales, Burns Philp, Commonwealth Scientific and Industrial Research Organisation, Arnott's Biscuits, Gist-Brocades and Goodman Fielder, 25 September 1997
WO/1997/033614, Use of Coxiella bacteria to treat autoimmune disease, Australian National University, 18 September 1997
WO/1997/032979, Inhibition of proliferation of cells, University of New South Wales, 12 September 1997
WO/1997/029767, Stabilised growth hormone formulation and method of preparation thereof, CSL Ltd and Monash University, 21 August 1997
WO/1997/029735, Dermal penetration enhancers and drug delivery systems involving same, Monash University, 21 August 1997
WO/1997/028190, Cytokine antagonists and agonists, Medvet Science Pty Ltd, 7 August 1997
WO/1997/028185, Anti-microbial protein, Cooperative Research Centre for Plant Pathology, 7 August 1997
WO/1997/026886, Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria, Pharmacy and Therapeutic Advisory Consultancy Pty Ltd, 31 July 1997
WO/1997/025339, Composition and method for delivery of nucleic acids, Commonwealth Scientific and Industrial Research Organisation, 17 July 1997
WO/1997/024373, Monoclonal antibody antagonists to haemopoietic growth factors, Medvet Science Pty Ltd, 10 July 1997
WO/1997/022701, Equine rhinovirus 1 proteins, University of Melbourne, 26 June 1997
WO/1997/022345, Phospholipid and propylene glycol based lubricant, Macnaught Medical Pty Ltd, 26 June 1997
WO/1997/021727, Mycoplasma recombinant polypeptide vaccines, University of Melbourne, 19 June 1997
WO/1997/020050, Therapeutic and diagnostic compositions, Daratech Pty Ltd and Pig Research and Development Corporation, 5 June 1997
WO/1997/019177, Synthetic mammalian α-n-acetylglucosaminidase and genetic sequences encoding same, Women's and Children's Hospital, 29 May 1997
WO/1997/017406, UV absorbing compositions, M & J Bos Consultants Pty Ltd, 15 May 1997
WO/1997/016977, Liquid colostrum for dairy products, Northfield Laboratories Pty Ltd, 15 May 1997
WO/1997/016542, Diagnostics and treatments of periodontal disease, University of Melbourne, Victorian Dairy Industry Authority, 9 May 1997
WO/1997/016532, Immunity against Actinobacillus pleuropneumoniae's RTX-toxin APX, Commonwealth Scientific and Industrial Research Organisation and Pig Research and Development Corporation, 9 May 1997
WO/1997/016531, Immunity against Pasteurella haemolytica leukotoxin, Commonwealth Scientific and Industrial Research Organisation and Pig Research and Development Corporation, 9 May 1997
WO/1997/016064, Methods and compositions for the reduction of xenotransplantation rejection, Mount Sinai Medical Center and Austin Research Institute, 9 May 1997
WO/1997/015663, A novel haemopoietin receptor and genetic sequences encoding same, Amrad, 1 May 1997
WO/1997/014438, Production of analgesic synergy by co-administration of sub-analgesic doses of a mu opioid agonist and a kappa-2 opioid agonist, University of Queensland and The Lynx Project Ltd, 24 April 1997
WO/1997/014415, Analgesic immediate and controlled release pharmaceutical composition, F.H. Faulding & Co., 24 April 1997
WO/1997/013744, 3-amino-propoxyphenyl derivatives (i), University of Melbourne, 17 April 1997
WO/1997/012972, Regulated genes and uses thereof, Salvatore Oliviero and University of Siena, 10 April 1997
WO/1997/011963, Anti-galα(1,3)gal antibody binding peptides, Austin Research Institute, 3 April 1997
WO/1997/006826, Gene therapy using ovine adenoviral vectors, Commonwealth Scientific and Industrial Research Organisation, 27 February 1997
WO/1997/005250, Receptor ligand VEGF-C, Kari Alitalo, Vladimir Joukov, and University of Helsinki, 13 February 1997
WO/1997/005164, Papillomavirus polyprotein constructs, CSL Ltd and University of Queensland, 13 February 1997
WO/1997/004776, Radioprotectors, Inner and Eastern Health Care Network, 13 February 1997
WO/1997/002831, Herbal compositions for hepatic disorders, Cathay Herbal Laboratories Pty Ltd, 30 January 1997
WO/1997/000695, Haemopoietic growth factor antagonists and uses therefor, Bresagen and Medvet Science Pty Ltd, 9 January 1997
WO/1997/000693, Novel formulation for peptide release, Peptech, 9 January 1997
WO/1997/000086, Immunogenic preparation and method for improving the productivity of ruminant animals, Commonwealth Scientific and Industrial Research Organisation, 3 January 1997
WO/1997/000052, Denture retaining composition, Confi-Dent Pty Ltd, 3 January 1997
WO/1996/040906, Optimized minizymes and miniribozymes and uses thereof, Commonwealth Scientific and Industrial Research Organisation, 19 December 1996
WO/1996/039499, TNF-α ribozymes, TNF-α ribozyme binding protein and degradation resistant mRNA derivatives linked to TNF-α ribozymes, Gene Shears Pty Ltd, 12 December 1996
WO/1996/038186, Chemotherapeutic compositions, Chemeq, 5 December 1996
WO/1996/034614, Method of preventing or treating alimentary tract damage due to chemotherapy or radiation, Gropep, 7 November 1996
WO/1996/033726, Preparation and use of sulfated oligosaccharides, Australian National University, 31 October 1996
WO/1996/033220, Protective Helicobacter antigens, CSL Ltd and University of New South Wales, 24 October 1996
WO/1996/029392, Methods for microbial regulation, University of New South Wales, 26 September 1996
WO/1996/028476, Process for glucan preparation and therapeutic uses of glucan, Novogen, 19 September 1996
WO/1996/028472, Antigen composition against Mycoplasma, University of Melbourne, 19 September 1996
WO/1996/028177, Method and vaccine for prevention of over-production of acid in the rumen or gut of animals, University of New England, 19 September 1996
WO/1996/027666, Novel avian cytokines and genetic sequences encoding same, Commonwealth Scientific and Industrial Research Organisation, 12 September 1996
WO/1996/027376, Corticosteroid-containing pharmaceutical composition, Medeva plc, 12 September 1996
WO/1996/026218, Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (IDDM), Amrad, 29 August 1996
WO/1996/022306, Novel peptide, Northern Sydney Area Health Service, 25 July 1996
WO/1996/022303, Therapeutic compound - fatty acid conjugates, Commonwealth Scientific and Industrial Research Organisation, 25 July 1996
WO/1996/020703, Compounds for veterinary and medicinal applications, Australian Biomedical Company Pty Ltd, 11 July 1996
WO/1996/019496, Variants of Human Papilloma Virus antigens, CSL Ltd and University of Queensland, 27 June 1996
WO/1996/019471, Polymerisable monomers and polymers, Commonwealth Scientific and Industrial Research Organisation, 27 June 1996
WO/1996/017855, Anti-tumour agents, Griffith University, 13 June 1996
WO/1996/017057, SOX-9 gene and protein and use in the regeneration of bone or cartilage, University of Queensland, 6 June 1996
WO/1996/016950, HIV protease inhibitors, University of Queensland, 6 June 1996
WO/1996/014062, A delivery system for antimethanogenic agents, Commonwealth Scientific and Industrial Research Organisation, 17 May 1996
WO/1996/013507, Synthetic polyunsaturated fatty acid analogues, Peptech and Women's and Children's Hospital Adelaide, 9 May 1996
WO/1996/012466, Controlled release container with core and outer shell, Daratech Pty Ltd, 2 May 1996
WO/1996/011944, Synthetic peptides and vaccines comprising same, Queensland Institute of Medical Research, Commonwealth Scientific and Industrial Research Organisation, University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Biotech Australia Pty Ltd and CSL Ltd, 25 April 1996
WO/1996/011015, Hydration compositions for human or animal bodies, Aqua Connexions Pty Ltd, 18 April 1996
WO/1996/008512, Polypeptides with Fc binding ability, Austin Research Institute, 21 March 1996
WO/1996/008261, Probiotic compositions, University of New South Wales, Burns Philp, Commonwealth Scientific and Industrial Research Organisation, Arnott's Biscuits, Gist-Brocades and Goodman Fielder, 21 March 1996
WO/1996/006937, Improvements in production of proteins in host cells, Austin Research Institute, 7 March 1996
WO/1996/006629, High-affinity response-selective C-terminal analogs of c5a anaphylatoxin, University of Nebraska and University of Queensland, 7 March 1996
WO/1996/006185, Assay for the detection of proteases, Commonwealth Scientific and Industrial Research Organisation, 29 February 1996
WO/1996/005218, Delivery of nucleic acids, Commonwealth Scientific and Industrial Research Organisation, 22 February 1996
WO/1996/001636, A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders, Royal Children's Hospital, 25 January 1996
WO/1995/035131, Controlled release device and method, Unasco Pty Ltd, 28 December 1995
WO/1995/034595, Antiviral dendrimers, Biomolecular Research Institute, 21 December 1995
WO/1995/033482, Treatment and prevention of Helicobacter infection, CSL Ltd and University of New South Wales, 14 December 1995
WO/1995/031476, Recombinant Papilloma Virus L1, University of Queensland, 23 November 1995
WO/1995/030436, An adjuvant, Commonwealth Scientific and Industrial Research Organisation, 16 November 1995
WO/1995/029933, Modified milk growth factor, Gropep, 9 November 1995
WO/1995/027483, Carotenoid agent for inhibiting the conversion of epithelial cells to tumours, Lance Schlipalius, Julie Buckmeier and Frank Meyskens Jr, 19 October 1995
WO/1995/024925, Cytotoxic T-cell epitopes, Queensland Institute of Medical Research, Commonwealth Scientific and Industrial Research Organisation, University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Biotech Australia Pty Ltd and CSL Ltd, 21 September 1995
WO/1995/022993, Method and device for the provocation of air passage narrowing and/or the induction of sputum, Central Sydney Area Health Service, 31 August 1995
WO/1995/022969, Method of treatment of cancer as well as method of inhibition of lactation in mammals, University of Queensland and Australian National University, 31 August 1995
WO/1995/022563, Antigenic preparation for treatment or prevention of Helicobacter infection, CSL Ltd and University of New South Wales, 24 August 1995
WO/1995/021912, Non-pathogenic strains of HIV-1, Macfarlane Burnet Centre for Medical Research and Australian Red Cross Society, 17 August 1995
WO/1995/021192, Malaria merozoite antigen subunit vaccine, Saramane Pty Ltd, 10 August 1995
WO/1995/020659, Modified Papilloma Virus L2 protein and VLPs formed therefrom, University of Queensland and CSL Ltd, 3 August 1995
WO/1995/019841, Particulate material, Bruce Gray, 27 July 1995
WO/1995/018854, Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs, Gene Shears Pty Ltd, 13 July 1995
WO/1995/018145, Conjugates of human mucin and a carbohydrate polymer and their use in cancer treatment, Ilexus Pty Ltd, 6 July 1995
WO/1995/017208, Prophylaxis of allergic disease, TVW Telethon Institute for Child Health Research, 29 June 1995
WO/1995/015377, Plant arabinogalactan protein (AGP) genes, Albright & Wilson, 8 June 1995
WO/1995/015339, Antagonists to chaperonin 10, University of Queensland, 8 June 1995
WO/1995/015338, Chaperonin 10, University of Queensland, 8 June 1995
WO/1995/013818, A method for treating cardiac dysfunction and pharmaceutical compositions useful therefor, Baker Medical Research Institute, 26 May 1995
WO/1995/013801, Fatty acid delivery system, Commonwealth Scientific and Industrial Research Organisation, 26 May 1995
WO/1995/013798, Controlled release preparation, Cancer Research Institute, 26 May 1995
WO/1995/013096, Labelled diagnostic compositions and methods of their use, Peptide Delivery Systems Pty Ltd, 18 May 1995
WO/1995/011253, A method for enhancing neurone survival and agents useful for same, Walter and Eliza Hall Institute of Medical Research, 27 April 1995
WO/1995/011041, Method for improving utilisation of nutrients by ruminant or ruminant-like animals, Commonwealth Scientific and Industrial Research Organisation, 27 April 1995
WO/1995/009622, Polyunsaturated fatty acids and uses thereof, Peptech and Women's and Children's Hospital Adelaide, 13 April 1995
WO/1995/008632, Immunoreactive antigens of Hepatitis E Virus, Macfarlane Burnet Centre for Medical Research, 30 March 1995
WO/1995/008562, Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition, Anadis, 30 March 1995
WO/1995/008339, Treatment or prevention of Crohn's disease and/or ulcerative colitis, Peptech, 30 March 1995
WO/1995/008338, Method for the treatment or prevention of eczema/dermatitis, Peptech, 30 March 1995
WO/1995/004529, Composition for treatment of hangovers, Musashi Pty Ltd, 16 February 1995
WO/1995/004075, Haemopoietic growth factor antagonists, Medvet Science Pty Ltd, 9 February 1995
WO/1995/003824, Treatment of H. pylori associated gastroduodenal disease, CSL Ltd and University of New South Wales, 9 February 1995
WO/1995/003807, Treatment of Age-related Macular Degeneration, University of Sydney, 9 February 1995
WO/1994/029461, Method for specific silencing of genes by DNA methylation, Commonwealth Scientific and Industrial Research Organisation, 22 December 1994
WO/1994/028886, Use of natural products and related synthetic compounds for the treatment of cardiovascular disease, University of Sydney, 22 December 1994
WO/1994/028015, LHRH antagonists, Biotech Australia Pty Ltd, 8 December 1994
WO/1994/027613, Vitamin B12 mediated oral delivery systems for GCSF and EPO, Biotech Australia Pty Ltd, 8 December 1994
WO/1994/027598, Antiparasitic compositions, Commonwealth Scientific and Industrial Research Organisation, 8 December 1994
WO/1994/026776, Therapeutic compounds, Biomolecular Research Institute, Macfarlane Burnet Centre for Medical Research and Commonwealth Scientific and Industrial Research Organisation, 24 November 1994
WO/1994/023748, Administration of vaso-active agent and therapeutic agent, University of Queensland, 27 October 1994
WO/1994/021232, Water dispersible therapeutic compounds, Betatene, 29 September 1994
WO/1994/021231, Therapeutic agent for the treatment of melanomas, Betatene, 29 September 1994
WO/1994/018984, Ecdysones used to improve productivity of ruminants, Commonwealth Scientific and Industrial Research Organisation, 1 September 1994
WO/1994/018328, Protein Kinase C (iota), Garvan Institute of Medical Research, 18 August 1994
WO/1994/015636, Vaccine preparations, CSL Ltd, 21 July 1994
WO/1994/014958, Synthetic polynucleotides, University of Sydney, 7 July 1994
WO/1994/013688, DNA-armed ribozymes and minizymes, Gene Shears Pty Ltd, 23 June 1994
WO/1994/010331, Angiogenesis inhibitory antibodies, Australian National University, 11 May 1994
WO/1994/010314, Allergenic proteins and peptides from Johnson grass pollen, University of Melbourne, 11 May 1994
WO/1994/010301, TNF-α ribozymes and degradation resistant mRNA derivatives linked to TNF-α ribozymes, Gene Shears Pty Ltd, 11 May 1994
WO/1994/009149, Monoclonal antibody, Amrad, 28 April 1994
WO/1994/007921, Target binding polypeptide, Commonwealth Scientific and Industrial Research Organisation, 14 April 1994
WO/1994/005790, Cloning and sequencing of allergens of Dermatophagoides (house dust mite), Immulogic Pharmaceutical Corporation, 17 March 1994
WO/1994/005311, Retro-, inverso-, and retro-inverso synthetic peptide analogues, Deakin Research Ltd, 17 March 1994
WO/1994/003633, Assessment of trans-acting factors allelic variation, Garvan Institute of Medical Research, 17 February 1994
WO/1994/003160, Pelletised pharmaceutical composition, F.H. Faulding & Co., 17 February 1994
WO/1994/001464, Leukaemia Inhibitory Factor-binding protein, Amrad, 20 January 1994
WO/1994/000146, Treatment for sensitive teeth, University of Melbourne and Victorian Dairy Industry Authority, 6 January 1994
WO/1993/024650, Therapeutic compositions, Monash University, 9 December 1993
WO/1993/024528, Equine herpesvirus glycoproteins, University of Melbourne, 9 December 1993
WO/1993/024454, High cis beta-carotene composition, Betatene, 9 December 1993
WO/1993/023069, Health supplements containing phyto-oestrogens, analogues or metabolites thereof, Graham Kelly, 25 November 1993
WO/1993/020102, Peptide T and related peptides in the treatment of inflammation, including Multiple Sclerosis, Peptech and Drug Royalty Corporation, 14 October 1993
WO/1993/017108, Analogous peptides of the internal image of a viral protein, Centre National de la Recherche Scientifique and Monash University, 2 September 1993
WO/1993/016179, Mammalian Sos - a regulator/effector of tyrosine kinase signalling, Howard Florey Institute of Experimental Physiology and Medicine, 19 August 1993
WO/1993/012806, A method for the treatment of tumours and sarcomas, Amrad, 8 July 1993
WO/1993/010244, Synthetic alpha-l-iduronidase and genetic sequences encoding same, Women's and Children's Hospital, 27 May 1993
WO/1993/009227, Human neuropeptide y-y1 receptor, Garvan Institute of Medical Research, 13 May 1993
WO/1993/007833, Biocompatible implant for the timing of ovulation in mares, Peptech, 29 April 1993
WO/1993/007171, Human Il-3 variants, Medvet Science Pty Ltd, 15 April 1993
WO/1993/006856, Treating ophthalmic fibrosis using interferon-alpha, Mark Gillies, Nigel Morlet and Marc Sarossy, 15 April 1993
WO/1993/004690, Method for the treatment of the complications and pathology of diabetes, Peptech and King's College London, 18 March 1993
WO/1993/004174, Ryegrass pollen allergen, University of Melbourne, 4 March 1993
WO/1993/002706, Self-adjuvanting peptide vaccine delivery system and production thereof, Commonwealth Scientific and Industrial Research Organisation, 18 February 1993
WO/1993/002184, Papilloma virus vaccine, University of Queensland and CSL Ltd, 4 February 1993
WO/1993/001215, Pla2 inhibitory compounds, Garvan Institute of Medical Research, 21 January 1993
WO/1993/001211, Peptide which abrogates TNF and/or LPS toxicity, Peptech, 21 January 1993
WO/1993/000425, A novel receptor-type tyrosine kinase and use thereof, Amrad, 7 January 1993
WO/1993/000084, Methods and compositions for treating malaria and other diseases, Adelaide Children's Hospital, 7 January 1993
WO/1992/018526, Production of phosphopeptides from casein, University of Melbourne and Victorian Dairy Industry Authority, 29 October 1992
WO/1992/017167, Oral delivery systems for microparticles, Biotech Australia Pty Ltd, 15 October 1992
WO/1992/017165, A single dose vaccination system, CSL Ltd and Monash University, 15 October 1992
WO/1992/015681, Human galanin, cDNA clones encoding human galanin and a method of producing human galanin, Garvan Institute of Medical Research, 17 September 1992
WO/1992/014485, A method for the diagnosis and treatment of Glutamic Acid Decarboxylase autoantigen associated diseases, Amrad, 3 September 1992
WO/1992/013890, Nematode vaccine, Biotech Australia Pty Ltd and Commonwealth Scientific and Industrial Research Organisation, 20 August 1992
WO/1992/013889, Nematode vaccine, Biotech Australia Pty Ltd and Commonwealth Scientific and Industrial Research Organisation, 20 August 1992
WO/1992/010511, Compounds and compositions which inhibit bone resorption, University of Melbourne and Genentech, 25 June 1992
WO/1992/007582, Corynebacteria and related organisms as vaccine vectors, Commonwealth Scientific and Industrial Research Organisation, 14 May 1992
WO/1992/005192, T-cell epitopes, Biotech Australia Pty Ltd, 2 April 1992
WO/1992/004376, Novel chemotactic factor, Heart Research Institute, 19 March 1992
WO/1992/003458, Non-A, Non-B Hepatitis Virus antigen, diagnostic methods and vaccines, New York Blood Center and Pharmacia, 5 March 1992
WO/1992/002624, Cloning and expression of toxoplasma antigens and use of recombinant antigens, Flinders University, 20 February 1992
WO/1992/002623, Cloning and expression of a rhoptry associated protein of P. falciparum, Saramane Pty Ltd, 20 February 1992
WO/1992/000994, Growth-promoting agent, Gropep, 23 January 1992
WO/1991/019789, Endonucleases, Commonwealth Scientific and Industrial Research Organisation, 26 December 1991
WO/1991/018097, CD46 variants, University of Melbourne, 28 November 1991
WO/1991/016073, Oral vaccine comprising antigen surface-associated with red blood cells, University of Newcastle, 31 October 1991
WO/1991/014443, A method for regulating neuron development and maintenance, Amrad, 3 October 1991
WO/1991/013908, Neutrophil stimulating peptides, Peptech, 19 September 1991
WO/1991/012018, Method for treating intestinal diseases, Gropep, 22 August 1991
WO/1991/008752, Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor, Amrad, 27 June 1991
WO/1991/007186, Anti-inflammatory compositions and methods, University of Melbourne, 30 May 1991
WO/1991/002078, Tumour Necrosis Factor binding ligands, Peptech, 21 February 1991
WO/1991/002063, Improvements in Granulocyte-Macrophage Colony-Stimulating Factor receptor and derivatives thereof, Amrad, 21 February 1991
WO/1990/015140, Production of IBDV vp2 in highly immunogenic form, Commonwealth Scientific and Industrial Research Organisation, 13 December 1990
WO/1990/014433, Monoclonal antibodies which recognise malignant cells from bladder carcinomas, University of Sydney and Central Sydney Area Health Service, 29 November 1990
WO/1990/012321, Halogenated DNA ligand radiosensitisers for cancer therapy, Cancer Institute, University of Melbourne and Anti-Cancer Council of Victoria, 18 October 1990
WO/1990/009995, UV-absorbing compounds and compositions, ICI Australia and Australian Institute of Marine Science, 7 September 1990
WO/1990/008188, Leukaemia Inhibitory Factor from livestock species and use thereof to enhance implantation and development of embryonic cells, Amrad, 26 August 1990
WO/1990/003433, Vaccine, Biotechnology Australia Pty Ltd and Commonwealth Scientific and Industrial Research Organisation, 5 April 1990
WO/1990/001335, Treatment of gastro-intestinal disorders, Thomas Borody, 22 February 1990
WO/1990/001319, Use of castanospermine as an anti-inflammatory and immunosuppressant agent, Australian National University, 22 February 1990
WO/1990/000569, Acid-Labile Subunit (ALS) of Insulin-like Growth Factor (IGF) binding protein complex, Central Sydney Area Health Service, 25 January 1990
WO/1989/005852, Ribozymes, Macphillamy Cummins & Gibson, 29 June 1989
WO/1989/001514, Molecular cloning of human rotavirus serotype 4 gene 9 encoding vp7, the major outer capsid neutralisation specific glycoprotein and expression of vp7 and fragments thereof for use in a vaccine, University of Melbourne and University of Sydney, 23 February 1989
WO/1989/000163, Vaccines against animal parasitic nematodes, Biotechnology Australia Pty Ltd and Commonwealth Scientific and Industrial Research Organisation, 12 January 1989
WO/1988/009376, Method and compositions for making ACSF and ACSF antagonists, Genentech and University of Melbourne, 1 December 1988
WO/1988/007602, Process for dyeing wool and other keratin fibres, Commonwealth Scientific and Industrial Research Organisation, 6 October 1988
WO/1988/007548, Leukaemia Inhibitory Factor, Amrad, 6 October 1988
WO/1988/007060, Anti-inflammatory compounds and compositions, Arthropharm Pty Ltd, 22 September 1988
WO/1988/006627, Plant gum material and use thereof in food products, Bio Polymers Pty Ltd and Commonwealth Scientific and Industrial Research Organisation, 7 September 1988
WO/1988/005301, Sulphated polysaccharides having anti-metastatatic and/or anti-inflammatory activity, Australian National University, 28 July 1988
WO/1988/004689, Primary biliary cirrhosis autoantigen, Amrad, 30 June 1988
WO/1988/003929, Vaccine containing tick antigens, Biotechnology Australia Pty Ltd and Commonwealth Scientific and Industrial Research Organisation, 2 June 1988
WO/1988/000971, Recombinant vaccine, Commonwealth Scientific and Industrial Research Organisation and Australian National University, 11 February 1988
WO/1988/000596, A protein active in humoral hypercalcemia of malignancy PTHrP, University of Melbourne, 28 January 1988
WO/1987/006590, Immunopotentiation, Bioenterprises Pty Ltd, 5 November 1987
WO/1987/002251, Oral delivery of biologically active substances bound to vitamin B12, or analogues thereof, Biotechnology Australia Pty Ltd, 23 April 1987
WO/1986/007060, Cloning and expression of host-protective immunogens of IBDV, Commonwealth Scientific and Industrial Research Organisation, 4 December 1986
WO/1986/006635, Oral vaccines, Biotechnology Australia Pty Ltd, 20 November 1986
WO/1986/006076, Recombinant inhibin, Biotechnology Australia Pty Ltd, Monash University, Prince Henry's Hospital and St. Vincent's Institute of Medical Research, 23 October 1986
WO/1985/005122, Rotavirus, University of Melbourne, 21 November 1985

New Zealand

WO/1998/035567, Gelling agents and gels containing them, University of Otago and Kiwitech Ltd, 20 August 1998
WO/1998/031799, Polynucleotides and polypeptides encoding receptors, Human Genome Sciences, 23 July 1998
WO/1998/025470, A method of biological control, Kelvin Duncan and Angus Macrae , 18 June 1998
WO/1998/015658, Compositions and methods for treating viral infections, Probe International, 16 April 1998
WO/1998/014202, Regulation of neural enzymes, University of Auckland, 9 April 1998
WO/1998/013056, Beta-glucan products and extraction processes from cereals, Gracelinc Ltd, 2 April 1998
WO/1998/008542, Compounds and methods for treatment and diagnosis of mycobacterial infections, Genesis Research & Development and Vialactia Bioscience, 5 March 1998
WO/1997/046204, Injectable compositions, Ashmont Holdings Ltd and Colin Harvey, 11 December 1997
WO/1997/040776, Synchronising of animal oestrus and intra vaginal devices useful therein, Michael Rathbone, Craig Bunt and Shane Burggraaf, 6 November 1997
WO/1997/038704, Treatment of bone disorders with adrenomedullin, University of Auckland and Tulane University, 23 October 1997
WO/1997/011709, Anthelmintic macrocyclic lactone compositions, Ashmont Holdings Ltd, 3 April 1997
WO/1997/007101, Radiation-activated cytotoxin therapy, University of Auckland, 27 February 1997
WO/1996/027377, Methods and compositions for sedating, anaesthetising and euthanising aquatic organisms, New Zealand Institute for Crop and Food Research, 12 September 1996
WO/1996/019235, Enhancement of fetal growth by administration of insulin-like growth factor-1 (IGF-1), University of Auckland, 27 June 1996
WO/1996/002269, Therapeutic method and compounds of use therein, University of Auckland, 1 February 1996
WO/1995/024216, Prevention of diabetes, University of Auckland, 14 September 1995
WO/1995/023590, Anthelmintic preparation, Bomac Laboratories, 8 September 1995
WO/1995/019763, Device for administration of beneficial materials to ruminants, New Zealand Pastorial Agriculture Research Institute, 27 July 1995
WO/1995/017511, Mycobacteria virulence factors and a method for their identification, Agresearch New Zealand Pastoral Agriculture Research Institute and Yeshiva University, 29 June 1995
WO/1995/017204, Composition and methods to improve neural outcome, University of Auckland, 29 June 1995
WO/1995/012409, Dendritic cell-specific antibodies and methods for their preparation, Derek Hart, 11 May 1995
WO/1994/027954, Nitrobenzyl mustard quaternary salts and their use as hypoxia-selective cytotoxic agents, University of Auckland, 8 December 1994
WO/1993/017030, Immunological detection of organophosphates, Horticulture and Food Research Institute of New Zealand, 2 September 1993
WO/1993/008284, M. paratuberculosis promoter and use thereof in immunogenic sequence expression, Institut Pasteur and Massey University, 29 April 1993
WO/1993/002695, IGF-1 to improve the neural condition, Genentech and University of Auckland, 18 February 1993

WO/1998/035567, Gelling agents and gels containing them, University of Otago and Kiwitech Ltd, 20 August 1998
WO/1998/031799, Polynucleotides and polypeptides encoding receptors, Human Genome Sciences, 23 July 1998
WO/1998/025470, A method of biological control, Kelvin Duncan and Angus Macrae , 18 June 1998